Top Markets
#1 Helium Helium +83.36%
#2 Seeker Seeker +52.14%
#3 Pons Pons +36.63%
#4 UnifAI Network UnifAI Network +29.95%
#5 TENDIES TENDIES +27.32%
#6 Tensor Tensor +23.80%
#7 Zylo Ecosystem Zylo Ecosystem +23.78%
#8 Bounce Bounce +17.72%
#9 pipedog pipedog +16.96%
#10 Songbird Songbird +15.11%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CHO Pharma, Inc. CHO Pharma, Inc.

CHO Pharma, Inc.

6586
Classifica tra le azioni #11104
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Prezzo delle azioni
$3.47
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$741.78M
Variazione (1 giorno)
-0.91%
Variazione (1 anno)
181.14%
Paese
TW
Scambia CHO Pharma, Inc. (6586)

Categoria

Healthcare
Il prezzo 6586 con la capitalizzazione del mercato della B
CHO Pharma, Inc. CHO Pharma, Inc.
6586
$3.47
Capitalizzazione di mercato di CHO Pharma, Inc.(6586)
Capitalizzazione di mercato: $741.78M
A partire dal August 2026, CHO Pharma, Inc. ha una capitalizzazione di mercato pari a $741.78M. Questo rende CHO Pharma, Inc. la 11104th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di CHO Pharma, Inc. dal 2017 al 2026
6586 in paragone con la classifica dei più popolari stocks
Il prezzo per 6586 Attivo B Capitalizzazione del mercato a B Risultati
CHO Pharma, Inc. CHO Pharma, Inc.
$24,596.31 $741.78M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.264T +709,526.02%
CHO Pharma, Inc. CHO Pharma, Inc.
$21,967.50 $741.78M
Apple Inc. Apple Inc.
AAPL
$4.701T +633,682.59%
CHO Pharma, Inc. CHO Pharma, Inc.
$19,518.56 $741.78M
Alphabet Inc. Alphabet Inc.
GOOG
$4.177T +563,028.51%
CHO Pharma, Inc. CHO Pharma, Inc.
$17,837.45 $741.78M
Microsoft Corporation Microsoft Corporation
MSFT
$3.817T +514,526.75%
CHO Pharma, Inc. CHO Pharma, Inc.
$13,393.44 $741.78M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.866T +386,313.06%